At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
MEDI0382 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Phase 2, Randomised, Double-blind, Placebo-controlled, and Open-label Active Comparator Study to Evaluate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
In Brief
A Phase 2 clinical trial evaluating MEDI0382, Placebo, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 51 participants across 3 sites in 3 countries.
Detailed Summary
A phase 2 study in two parts (A \& B) designed to evaluate the effect of MEDI0382 on Hepatic Glycogen Metabolism in subjects with Type 2 Diabetes Mellitus (T2DM). Approximately 20 subjects will be enrolled in Part A and approximately 30 subjects in Part B.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesNetherlands, Sweden, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartMay 2018
First PostedJun 2018
Primary CompletionApr 2021
TodayJul 2026
First PostedJun 14, 2018
Enrollment StartMay 31, 2018
Primary CompletionApr 14, 2021
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 8.0 years ago
Interventions
MEDI0382drug
MEDI0382 administered subcutaneously
Placebodrug
Placebo administered subcutaneously
Liraglutidedrug
Liraglutide administered subcutaneously